Sarmad Sadeghi, MD, PhD

Photo of Sarmad Sadeghi, MD, PhD
Title(s)Associate Professor of Clinical Medicine and Urology
SchoolKeck School of Medicine of Usc
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089-9172
Phone+1 323 865 0553
ORCID ORCID Icon0000-0003-2654-1991 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Sadeghi joined the faculty in the Division of Oncology at the University of Southern California in 2013. A clinician-scientist with NIH R01 funding, his clinical and research focus centers on genitourinary malignancies, with particular expertise in bladder, kidney, and prostate cancers.
    He serves as principal investigator of the NIH R01 grant R01CA293348 and as study chair and principal investigator for multiple multicenter clinical trials, including SWOG S1937. A member of SWOG, he also holds the role of Genitourinary Group Chair for the California Cancer Consortium.
    Dr. Sadeghi is widely published, with numerous original articles and abstracts appearing in peer-reviewed journals and presented at international meetings.
    He earned his medical degree (MD) from Tehran University of Medical Sciences. He later completed a Master of Science (MS) in Health Informatics and a Doctor of Philosophy (PhD) in Public Health Management and Policy Sciences at the University of Texas Health Science Center at Houston. His postgraduate training included an internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation, followed by a hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute.

    Collapse Research 
    Collapse Featured Publications
    Collapse research activities and funding
    Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
    NIH R01CA293348Jun 1, 2025 - Apr 30, 2030
    Role: Study Chair and Principal Investigator
    A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma
    NIH/NCI SWOG S1937Feb 16, 2021 - Mar 13, 2026
    Role: Study Chair and Principal Investigator
    A randomized double blind phase II trial of axitinib +/- OX40 Ab in mRCC patients previously treated with VEGF and PD1/PDL1 Ab
    Pfizer Pfizer WI218033Jan 1, 2016 - Dec 31, 2026
    Role: Study Chair and Principal Investigator
    Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder
    NIH/NCI/CTEP NCI-9653/PHII-130Jun 1, 2015 - Mar 1, 2017
    Role: Study Chair and Principal Investigator
    A phase II trial of sEphB4-HSA in combination with Anti PD1 Antibody Pembrolizumab (MK-3475) in solid tumors
    Merck MISP-52662Jan 1, 2015 - Dec 31, 2025
    Role: Study Chair and Principal Investigator

    Collapse Featured Content 

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma. Clin Cancer Res. 2026 Sep 09. Klümper N, Büttner T, Rauch S, Zschäbitz S, Roghmann F, Bolenz C, Lange F, Rausch P, Zengerling F, Gaisa N, Hahn O, Schwab C, Scherping A, Toma M, Heers H, Ivanyi P, Niegisch G, Grunewald CM, Darr C, Paffenholz P, Weiten R, Füssel S, Thomas C, Sondermann M, Sommer U, Junker K, Schlack K, Casuscelli J, Aydogdu C, Niedersüß-Beke D, Rausch S, Kuppe C, Meeks J, Choy B, Sadeghi S, Gill P, Ritter M, Brägelmann J, Hölzel M, Hartmann A, Grünwald V, Saal J, Eckstein M. PMID: 42714834.
      View in: PubMed   Mentions:
    2. Comparative Effectiveness and Cost-Effectiveness of an Artificial Intelligence Workflow for Small Renal Mass Diagnosis on Computed Tomography. Urol Pract. 2026 Jun 03; 101097UPJ0000000000001031. Rich JM, Bajakian T, Gala T, Aminy M, Forsyth E, Raff E, Brunner J, Gill I, Oberai A, Duddalwar V, Sadeghi S. PMID: 42234468.
      View in: PubMed   Mentions:    Fields:    
    3. Systemic Therapy for Muscle-Invasive Urothelial Carcinoma of the Bladder (Muscle-Invasive Bladder Cancer): Insights From Real-World Data. JCO Oncol Pract. 2025 Nov 18; OP2500464. Sadeghi S, Lara PN, Necchi A, Gill PS, Flaig TW, Lerner SP, Aron M, Daneshmand S. PMID: 41252668.
      View in: PubMed   Mentions:    Fields:    
    4. End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2025 11 10; 43(32):3536-3544. Necchi A, Galsky MD, Dizman N, Aggen DH, Agarwal N, Al-Ahmadie H, Apolo AB, Ballas L, Bangs R, Black PC, Brausi M, Brembilla G, Cheng L, Chiti A, Cimadamore A, Colecchia M, Daneshmand S, Di Stasi S, Efstathiou JA, Filicevas A, Geynisman DM, Grivas P, Gupta S, Iasonos A, James ND, Lerner SP, Loriot Y, Makaroff LE, Maluf F, Moschini M, Ostrovnaya I, Pal SK, Plimack ER, Prakash G, Psutka SP, Rosenberg JE, Sadeghi S, Schmidt B, Schwartz LH, Sonpavde GP, St Laurent MP, Ye D, Spiess PE, Kamat AM. PMID: 40934451; PMCID: PMC12431632.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    5. Editorial Comment. J Urol. 2025 Sep; 214(3):306-307. Sadeghi S, Duddalwar V. PMID: 40386955.
      View in: PubMed   Mentions:    Fields:    
    6. The outcomes of salvage robotic radical prostatectomy following radiation versus focal therapy: Does the primary treatment modality matter? BJUI Compass. 2025 May; 6(5):e70019. Ghoreifi A, Ramacciotti LS, Kaneko M, Medina LG, Cacciamani GE, Konganige S, Aron M, Sadeghi S, Jadvar H, Djaladat H, Sotelo R, Desai MM, Gill IS, Aron M, Abreu AL. PMID: 40322501; PMCID: PMC12045929.
      View in: PubMed   Mentions:
    7. EphB4-ephrin-B2 are targets in castration resistant prostate cancer. Br J Cancer. 2025 May; 132(8):679-689. Li GX, Ma B, Zhang S, Liu R, Siddiqi IN, Sali A, El-Khoueiry A, Gross M, Salhia B, Sadeghi S, Gill PS. PMID: 40044981; PMCID: PMC11997055.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    8. USPSTF Recommendations and Colorectal Cancer in Younger Adults-Current Challenges and Future Opportunities. JAMA Netw Open. 2024 10 01; 7(10):e2436305. Sadeghi S, Barzi A. PMID: 39361287.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    9. EphrinB2: Expression of a novel potential target in renal cell carcinoma. Indian J Urol. 2023 Jul-Sep; 39(3):223-227. Gupta C, Sali AP, Jackovich A, Ma B, Sadeghi S, Quinn D, Gill P, Gill I. PMID: 37575160; PMCID: PMC10419785.
      View in: PubMed   Mentions: 1  
    10. The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. Cancers (Basel). 2022 Dec 03; 14(23). Cacciamani GE, Barzi A, Eppler MB, Lara PN, Pan CX, Bhanvadia SK, Gill P, Aron M, Gill I, Sadeghi S. PMID: 36497466; PMCID: PMC9735798.
      View in: PubMed   Mentions: 2  
    11. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 01 20; 41(3):640-650. Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. PMID: 35984996.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    12. Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterol. 2020 11; 7(1). Barzi A, Yang D, Kim AW, Shah MA, Sadeghi S. PMID: 33148789; PMCID: PMC7643494.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis. Am J Clin Oncol. 2020 06; 43(6):428-434. Jiao X, Hay JW, Sadeghi S, Barzi A. PMID: 32187027; PMCID: PMC9303075.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. How to optimize cancer therapy when coronavirus hits the fan. Am J Manag Care. 2020 06; 26(5 Spec No.):SP167. Barzi A, Sadeghi S. PMID: 32639133.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    15. EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. Pathol Res Pract. 2020 Jun; 216(6):152967. Gupta C, Sali A, Ma B, Jackovich A, Sadeghi S, Quinn D, Gill P, Gill I. PMID: 32362422; PMCID: PMC9084634.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clin Genitourin Cancer. 2020 10; 18(5):351-360.e3. Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS. PMID: 32146152; PMCID: PMC9135583.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    17. Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have? Eur Urol Focus. 2020 07 15; 6(4):623-626. Basu A, Sadeghi S. PMID: 31753690.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863. Barzi A, Lara PN, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S. PMID: 31398279; PMCID: PMC6941667.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). J Clin Oncol. 2019 10 10; 37(29):2682-2688. Sadeghi S, Groshen SG, Tsao-Wei DD, Parikh R, Mortazavi A, Dorff TB, Kefauver C, Hoimes C, Doyle L, Quinn DI, Newman E, Lara PN. PMID: 31390274; PMCID: PMC7006847.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    20. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1. Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. PMID: 31227432; PMCID: PMC7446934.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    21. Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. Urol Oncol. 2019 01; 37(1):1-11. Bazargani ST, Clifford TG, Djaladat H, Schuckman AK, Wayne K, Miranda G, Cai J, Sadeghi S, Dorff T, Quinn DI, Daneshmand S. PMID: 30470611; PMCID: PMC7474471.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    22. Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clin Adv Hematol Oncol. 2017 Jul; 15(7):543-551. Yu SS, Ballas LK, Skinner EC, Dorff TB, Sadeghi S, Quinn DI. PMID: 28749918; PMCID: PMC7523177.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    23. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. Clin Adv Hematol Oncol. 2017 Jun; 15(6):466-477. Yu SS, Dorff TB, Ballas LK, Sadeghi S, Skinner EC, Quinn DI. PMID: 28749907; PMCID: PMC7515771.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    24. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 07; 35(7):459.e15-459.e24. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn DI, Sadeghi S. PMID: 28284890; PMCID: PMC8942442.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 05 01; 123(9):1516-1527. Barzi A, Lenz HJ, Quinn DI, Sadeghi S. PMID: 28117881; PMCID: PMC6879196.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    26. Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). Barzi A, Sadeghi S, Kattan MW, Meropol NJ. PMID: 25794514; PMCID: PMC4402362.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsPHPublic Health
    27. Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A. PMID: 24188686.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    28. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. Hepgur M, Sadeghi S, Dorff TB, Quinn DI. PMID: 23788831; PMCID: PMC3684142.
      View in: PubMed   Mentions: 10  
    29. Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. Semin Oncol. 2012 Oct; 39(5):608-14. Sadeghi S, Garcia JA. PMID: 23040257.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. Cancer. 2012 Jul 01; 118(13):3277-82. Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, Rini BI. PMID: 22139966.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    31. Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. Sadeghi S, Barzi A, Kattan MW, Meropol NJ. PMID: 21372042.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    32. A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. Sadeghi S, Barzi A, Sadeghi N, King B. PMID: 16140572.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    33. Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. Sadeghi S, Barzi A, Smith JW. PMID: 16160263.
      View in: PubMed   Mentions: 1     Fields:    
    34. Mitral valve recurrence of a left atrial myxoma. Eur J Cardiothorac Surg. 2002 Mar; 21(3):568-73. Sadeghi N, Sadeghi S, Karimi A. PMID: 11888789.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Determinants of operative mortality following primary coronary artery bypass surgery. Eur J Cardiothorac Surg. 2002 Feb; 21(2):187-92. Sadeghi N, Sadeghi S, Mood ZA, Karimi A. PMID: 11825722.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    36. Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. Barzi A, Sadeghi S, King BR. PMID: 15458058.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Sarmad's Networks
    Concepts (169)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (25)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.